Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Versicor (VERS) -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (22)	1/15/2003 5:33:05 PM
From: Cacaito	Read Replies (1) \| Respond to of 83

Td, seems a very neat drug that could decrease complications, hospitalizations days and costs...if it works as expected AND they could avoid kidney and ear toxicities associated with vancomycin (or at least show a simmilar pattern as vancomycin). The trial is well designed and comparing it to Linezolid which is currently used for failure treatments for MRSA and VRSA and VRE (all resistant strains to current lines of drugs). Very good market if they are successful. Thank you, for the lead !!!